NDAORALTABLET
Approved
Dec 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ADVIL PM (advil pm) by GSK is cyclooxygenase inhibitors [moa]. First approved in 2005.
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADVIL PM is an oral tablet combining ibuprofen (a nonsteroidal anti-inflammatory drug) with a nighttime sleep aid, approved in 2005. It is indicated for temporary relief of minor aches and pains with accompanying sleeplessness. The product works via cyclooxygenase inhibition to reduce inflammation and pain while the adjunct component promotes sleep.
LOE Approaching
As an OTC product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on cost containment and line extension strategy rather than aggressive growth.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ADVIL PM currently has zero linked job openings, reflecting its mature, stable OTC market position rather than active growth hiring. Opportunities on this product are likely limited to retention roles focused on defending market share and managing the transition to generic competition.
Brand ManagerProduct Manager
Worked on ADVIL PM at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.